Michael Rauh


Myeloid cancers (MC) include myeloproliferative neoplasms, myelodysplastic syndromes (MDS) and acute myeloid leukemia. Diagnosis requires invasive bone marrow (BM) sampling and is reliant on subjective microscopy, especially for MDS. Dr. Rauh’s research vision is to enact a paradigm shift from reactive BM tests to proactive peripheral blood surveillance for MC; from subjective morphology to objective genetic criteria; and from supportive/late interventions to targeted/early cures. His research aims to develop novel somatic mutation and digital gene expression assays to improve MC diagnosis, risk and treatment stratification. Moreover, Dr. Rauh aims to elucidate clone-immune environment interactions to inform novel therapeutic directions.

Rauh Lab Website

Contact Information

Dr. Michael Rauh

michael [dot] rauhatqueensu [dot] ca

Telephone: 613-533-2818


2014 - Transformative Pathology Fellow, Ontario Institute for Cancer Research (OICR).
2011 - Fellow (Hematological Pathology), Royal College of Physicians of Canada.
2011 - Assistant Professor, Pathology and Molecular Medicine, Queen's University.
2011 - Attending Hematopathologist, Kingston General Hospital.
2011Translational Research Training in Hematology (TRTH), American Society of Hematology (ASH) and European Hematology Agency (EHA).
2007 - 2011Resident Physician , Hematological Pathology, University of Toronto.
1999 - 2007MD, University of British Columbia.
1999 - 2007PhD, Experimental Medicine , Terry Fox Laboratory/British Columbia Cancer Agency/UBC.
1996 - 1999MSc, Medical Science, McMaster University, Hamilton.

Research Output